Evidence map›Paper›PMID 20703919›Full record

ArticleJournal of medical systems2010

Achieving standardized medication data in clinical research studies: two approaches and applications for implementing RxNorm.

Rachel L Richesson, Susan B Smith, Jamie Malloy, Jeffrey P Krischer

Open access · greenAbstract read
In one paragraph

Article in Journal of medical systems, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Toward a unified understanding of drug-drug interactions: mapping Japanese drug codes to RxNorm concepts.Journal of the American Medical Informatics Association : JAMIA · 2024
    Article
  2. Review
  3. Article
  4. Use of standard drug vocabularies in clinical research: a case study in pediatrics.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2010
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rachel L RichessonDepartment of Pediatrics, University of South Florida, Tampa, FL, USA. richesrl@epi.usf.edu
Susan B Smith
Jamie Malloy
Jeffrey P Krischer
University of South Florida · US

Funding

Data Coordinating Center (DCC)for the Consortium for Identification of EnvironmenUC4DK095300 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2011 to 2011
$56.0M
Data Coordinating CenterU01DK063790 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2002 to 2006
$50.1M
RARE DISEASES DATA AND TECHNOLOGY COORDINATING CENTERU54RR019259 · NCRR · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2003 to 2008
$14.4M
The Environmental Determinants of Diabetes in Young (TEDDY0U01DK063863 · NIDDK · HOSPITAL DISTRICT OF SOUTHWEST FINLAND · PI TOPPARI, JORMA · 2003 to 2022
$13.5M
The Environmental Triggers of Diabetes (TEDDY) in SwedenU01DK063861 · NIDDK · UNIVERSITY OF WASHINGTON · PI LERNMARK, AKE · 2003 to 2022
$13.4M
THE TEDDY STUDY - COLORADO CLINICAL CENTERU01DK063821 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J · 2003 to 2022
$12.3M
The Environmental Determinants of Diabetes in Youth: Washington Clinical CenterU01DK063829 · NIDDK · PACIFIC NORTHWEST RESEARCH INSTITUTE · PI HAGOPIAN, WILLIAM A. · 2003 to 2022
$11.8M
Type 1 Diabetes triggers: diet modification in neonatesU01DK063836 · NIDDK · FORSCHERGRUPPE DIABETES E. V. · PI ZIEGLER, ANETTE · 2003 to 2022
$6.2M
The Environmental Triggers of Diabetes (TEDDY)UC4DK063861 · NIDDK · LUNDS UNIVERSITET · PI LERNMARK, AKE · 2013 to 2013
$5.7M
The Environmental Determinants of Diabetes in the Young (TEDDY) Colorado ClinicalUC4DK063821 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J · 2013 to 2013
$4.9M
The Environmental Determinants of Diabetes in Youth: Washington Clinical CenterUC4DK063829 · NIDDK · PACIFIC NORTHWEST RESEARCH INSTITUTE · PI HAGOPIAN, WILLIAM A. · 2013 to 2013
$4.6M
NCRR NIH HHS RR019259NCRR NIH HHS U54 RR019259NIDDK NIH HHS DK63790NIDDK NIH HHS HHSN267200700014CNIDDK NIH HHS U01 DK063790NIDDK NIH HHS U01 DK063821NIDDK NIH HHS U01 DK063829NIDDK NIH HHS U01 DK063836NIDDK NIH HHS U01 DK063861NIDDK NIH HHS U01 DK063863NIDDK NIH HHS UC4 DK063821NIDDK NIH HHS UC4 DK063829NIDDK NIH HHS UC4 DK063861NIDDK NIH HHS UC4 DK095300
6 · The paper itself

Abstract

The National Institutes of Health has proposed a roadmap for clinical research. Test projects of this roadmap include centralized data management for distributed research, the harmonization of clinical and research data, and the use of data standards throughout the research process. In 2003, RxNorm was named as a standard for codifying clinical drugs. Clinical researchers looking to implement RxNorm have few template implementation plans. Epidemiological studies and clinical trials (types of clinical research) have different requirements for model standards and best implementation tools. This paper highlights two different (epidemiological and intervention) clinical research projects, their unique requirements for a medication standard, the suitability of RxNorm as a standard for each, and application and process requirements for implementation. It is hoped that our experience of selecting and implementing the RxNorm standard to address varying study requirements in both domestic and international settings will be of value to other efforts.

Indexed as

Clinical Pharmacy Information SystemsRegistriesVocabulary, ControlledData CollectionHumansInformation DisseminationMedical Order Entry Systems

Identifiers

PMID20703919
PMCPMC2977947
OpenAlexW2108001657

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.